Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980354 | 0.85 | PNMT (0.42) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL27253986 | 0.82 | PNMT (0.41) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL19981574 | 0.79 | PNMT (0.44) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL19981887 | 0.79 | PNMT (0.44) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL31564255 | 0.78 | PNMT (0.43) | ALDH1A1KDM4EPNMTMAPT | |
| SCHEMBL11987810 | 0.77 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL17970202 | 0.77 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL11987739 | 0.77 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL13303489 | 0.77 | ALDH1A1 (0.49) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL31564547 | 0.75 | PNMT (0.41) | ALDH1A1NPC1RAB9APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365970-B1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| EP-2188267-B1 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | GILEAD CONNECTICUT INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ALDH1A1 450/4885NPC1 558/4885RAB9A 2542/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885NPC1 2024/4885RAB9A 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.